PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33164274-9 2021 Reduction in the expression of vimentin, beta-catenin, and HOTAIR was detected as the result of metformin treatment, but the snail showed a constant expression. Metformin 96-105 vimentin Homo sapiens 31-39 35178358-0 2021 Metformin is a Novel Suppressor for Vimentin in Human Gastric Cancer Cell Line. Metformin 0-9 vimentin Homo sapiens 36-44 35178358-3 2021 In this study, AGS gastric cancer cells were treated with metformin and vimentin-specific siRNA (vim-siRNA) for 48 h. The impact of metformin and vim-siRNA on vimentin downregulation in AGS cells were analyzed by quantitative PCR and Western blot. Metformin 58-67 vimentin Homo sapiens 159-167 35178358-3 2021 In this study, AGS gastric cancer cells were treated with metformin and vimentin-specific siRNA (vim-siRNA) for 48 h. The impact of metformin and vim-siRNA on vimentin downregulation in AGS cells were analyzed by quantitative PCR and Western blot. Metformin 132-141 vimentin Homo sapiens 159-167 35178358-5 2021 The results showed that inhibition of vimentin due to metformin was comparable with the vim-siRNA. Metformin 54-63 vimentin Homo sapiens 38-46 35178358-7 2021 Our finding for the first time indicated that metformin can be an alternative to specific siRNA for inhibition of vimentin expression and migration of AGS cell line. Metformin 46-55 vimentin Homo sapiens 114-122 30569135-3 2019 Additionally, metformin attenuated the EMT process, characterized by a decrease of mesenchymal marker Vimentin and an increase in the expression of an epithelial marker. Metformin 14-23 vimentin Homo sapiens 102-110 30625181-6 2019 Similarly, metformin treatment suppressed expressions of anti-apoptotic genes BCL2 and Bcl-xL, and mesenchymal genes vimentin, N-cadherin, Zeb1 and Zeb2 with simultaneous enhancement of apoptotic caspase 3 and Bax, and epithelial genes E-cadherin and keratin 19 expressions, confirming an inhibitory effect of metformin in tumorigenesis. Metformin 11-20 vimentin Homo sapiens 117-125 31939444-10 2019 Metformin attenuated transforming growth factor-beta1 induced decrease of E-cadherin and increase of Vimentin proteins. Metformin 0-9 vimentin Homo sapiens 101-109 30625181-9 2019 Similarly, cholesterol treatment inverted metformin-reduced several gene expressions (e.g., Bcl-xL, BCL2, Zeb1, vimentin, and BMI-1). Metformin 42-51 vimentin Homo sapiens 112-120 30017802-8 2018 The up-regulation of E-cadherin and the down-regulation of vimentin for both SW480 and HCT116 cells revealed the anti-EMT abilities of metformin. Metformin 135-144 vimentin Homo sapiens 59-67 28011481-6 2017 A low dose of metformin significantly increased anoikis and inhibited migration/ invasion of CCA cells that was in concert with the decrease of vimentin, matrix metalloproteinase (MMP)-2 and -7. Metformin 14-23 vimentin Homo sapiens 144-152 29635803-9 2018 Metformin inhibited vimentin expression in both normal and tumor cells. Metformin 0-9 vimentin Homo sapiens 20-28 28043910-3 2017 In this study, we demonstrated that metformin is capable of inhibiting prostate cancer cell migration and invasion by repressing EMT evidenced by downregulating the mesenchymal markers N-cadherin, Vimentin, and Twist and upregulating the epithelium E-cadherin. Metformin 36-45 vimentin Homo sapiens 197-205 28042775-6 2017 RESULTS: There was a lower protein expression of ROCK-1, vimentin, CD44 and CD24 in both cell lines after treatment with metformin and Y27632. Metformin 121-130 vimentin Homo sapiens 57-65 28744307-1 2017 OBJECTIVES: We aimed to explore the association between metformin treatment and epithelial-mesenchymal transition (EMT) phenotype and further appraise the prognostic values of metformin and EMT markers E-cadherin and vimentin for colorectal cancer (CRC) in clinical practice. Metformin 56-65 vimentin Homo sapiens 217-225 27643646-8 2016 Metformin reduced EMT in the cell lines and regulated the expression of the EMT-related epithelial markers, E-cadherin and Pan-keratin; the mesenchymal markers, N-cadherin, fibronectin, and vimentin; and the EMT drivers, Twist-1, snail-1, and ZEB-1. Metformin 0-9 vimentin Homo sapiens 190-198 25201727-7 2014 Metformin could inhibit TGF-beta-induced EMT in Vcap cells, as manifested by inhibition of the increase of N-cadherin (p=0.013), Vimentin (p=0.002) and the decrease of E-cadherin (p=0.0023) and beta-catenin (p=0.034) at mRNA and protein levels. Metformin 0-9 vimentin Homo sapiens 129-137 26718286-13 2015 Metformin was also associated with a reduction of snail2, twist, and vimentin in CD44(+)CD117(+) ovarian CSCs in vivo. Metformin 0-9 vimentin Homo sapiens 69-77